Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc. | EDG-7500 - (CIRRUS-HCM) | Hypertrophic Cardiomyopathy (HCM) | Phase 2 | Data Released | Oral | Cardiology |
| eFFECTOR Therapeutics Inc. | Zotatifin (eFT226) combined with fulvestrant and abemaciclib | acute myeloid leukemia (AML) | Phase 2b | Ongoing | Intravenous | Oncology |
| eFFECTOR Therapeutics Inc. | Tomivosertib (MNK1/2) - (KICKSTART) | Non-small cell lung cancer (NSCLC) | Phase 2b | Trial Discontinued | Oral | Oncology |
| eFFECTOR Therapeutics Inc. | Zotatifin with abemaciclib and letrozole | Estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer | Phase 2 | Trial Planned | Intravenous | Oncology |
| Eiger BioPharmaceuticals Inc. | Ubenimex - ULTRA | Secondary lymphedema | Phase 2 | Oral | N/A | |
| Eiger BioPharmaceuticals Inc. | Ubenimex - LIBERTY | Pulmonary arterial hypertension (PAH) | Phase 2 | Oral | Cardiology | |
| Eiger BioPharmaceuticals Inc. | MYDICAR - CUPID 2 Trial | Ischemic or dilated cardiomyopathy | Phase 2b | Intracoronary infusion | Cardiology | |
| Eiger BioPharmaceuticals Inc. | Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - (LIFT) | Hepatitis delta virus (HDV) | Phase 2 | Oral | Antiviral |
